+ Watch INSM
on My Watchlist
Insmed Incorporated, a biopharmaceutical company, is focused on developing and commercializing novel, targeted inhalation therapies.
Insmed stock has been volatile since the company first reported in August that the FDA had placed their phase III antibiotic on clinical hold due to a cancer signal in rat studies. The looming predicament of a non-existent pipeline is counterbalanced by the company's substantial cash reserves, 85M as of the last quarterly statement. The share price has been volatile, bouncing from 3 to 5 and back, and I've successfully red-thumbed twice. At the current low end of recent range, market cap of 77M is significantly lower than cash and I expect that cash position to provide a buffer to approaching broad market declines.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions